再生元PD-1抑制剂Libtayo三期临床成功

Industry Investment Rating - The report maintains a positive outlook on the pharmaceutical industry [1][5] Core Views - The pharmaceutical sector outperformed the CSI 300 index by 0 07 percentage points on January 17 2025 with a gain of 0 38% [1] - Sub-sectors such as other biological products (+1 33%) medical consumables (+1 14%) and blood products (+0 87%) led the gains while hospitals (-0 28%) pharmaceutical distribution (-0 18%) and medical equipment (-0 12%) lagged [1] - Top gainers included Huluwa (+10 02%) Rundo Pharmaceutical (+9 99%) and Asia-Pacific Pharmaceutical (+9 90%) while top decliners were Xin Ganjiang (-6 19%) Kangwei Century (-4 42%) and BGI Manufacturing (-4 26%) [1] Industry News - Regeneron announced positive Phase 3 clinical trial results for its PD-1 inhibitor Libtayo (Cemiplimab) in high-risk cutaneous squamous cell carcinoma (CSCC) patients showing statistically significant and clinically meaningful improvement in disease-free survival (DFS) [2] - Libtayo is the first immunotherapy to demonstrate such benefits in the adjuvant treatment of high-risk CSCC patients [2] Company News - Junshi Biosciences (688336) forecasted 2024 revenue of 1 949 billion yuan a 29 71% YoY increase with a net loss of 1 292 billion yuan a 43 42% YoY reduction in losses [2] - Ascentage Pharma (002755) received NMPA approval for its third-generation EGFR TKI Liotinib for treating EGFR-mutated non-small cell lung cancer (NSCLC) [2] - Zhixiang Jintai (688443) projected 2024 revenue between 28 62 million yuan and 31 64 million yuan a YoY increase of 2262 72%-2511 43% with a net loss ranging from 731 28 million yuan to 858 46 million yuan [3] - Yixintang (002727) proposed a share buyback plan of 80 million yuan to 150 million yuan to maintain company value and shareholder rights [3]